Trials / Conditions / Refractory Central Nervous System Lymphoma
Refractory Central Nervous System Lymphoma
5 registered clinical trials studyying Refractory Central Nervous System Lymphoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Unknown | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma NCT04845139 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Active Not Recruiting | Acalabrutinib in CNSL NCT04906902 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma NCT03770416 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Cente NCT03558750 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Active Not Recruiting | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |